The accepted sine qua non for estimating the difference in efficacy between a new and a standard treatment is a randomized controlled clinical trial.
Yet in some situations it is either practically or ethically impossible to conduct such a trial.
For example, patients who are desperately ill may decline to participate when they learn they may not receive the new treatment, especially when that treatment, especially when that treatment is readily available outside the experimental protocol.
Likewise, in a prophylactic trial of a promising vaccine, recruitment of persons at greater risk may falter or fail.
Our objective is to demonstrate that a rigorous comparaison of treatments may still be attainable.
The features of a controlled clinical or prophylactic trial are reviewed from the perspectives of Food and Drug Administration regulations, ethical considerations, and practical problems.
An explicit risk-based allocation method of design and analysis is proposed, one guaranteeing that all subjects at greater risk will receive the new treatment.
Under certain conditions, a risk-based allocation trial can furnish consistent estimates of both standard and experimental treatment effects for those at greater risk while avoiding certain difficulties caused by randomized treatment allocation.
Mots-clés Pascal : Nouveauté, Médicament, Vaccin, Chimiothérapie, Traitement, Prévention, Essai clinique, Risque élevé, Distribution, Homme, Méthodologie, Modèle statistique, Recrutement
Mots-clés Pascal anglais : Novelty, Drug, Vaccine, Chemotherapy, Treatment, Prevention, Clinical trial, High risk, Distribution, Human, Methodology, Statistical model, Recruitment
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0273300
Code Inist : 002B30A08. Création : 199608.